ProSciento

ProSciento is a leading, science-driven contract research organization (CRO) dedicated to metabolic disease clinical trials. It differentiates itself through a deep focus on obesity, diabetes, and steatotic liver disease, offering specialized methods like doubly labeled water for energy expenditure measurement and direct patient access. The company operates globally, supporting clients from early development through Phase 2b and augmenting Phase 3 trials, with an unwavering commitment to advancing therapeutics that improve patient lives.

A specialized suite of clinical research methodologies focused on metabolic diseases, including gold-standard techniques like Doubly Labeled Water (DLW) for energy expenditure measurement, deep expertise in the 'Metabolic Continuum' for trial design, direct patient access, and integrated global operational capabilities.

ProSciento competes in a segment of the CRO market defined by metabolic disease expertise. It differentiates itself from large, diversified CROs (like IQVIA, PPD) through its deep, exclusive focus and specialized methodologies. It also competes with smaller consulting firms and niche providers, but its full-service, global operational capabilities provide a scale advantage within its niche.